Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
118.09
-0.13 (-0.11%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
62
63
Next >
Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
September 02, 2024
Eli Lilly is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepbound.
Via
Benzinga
Exposures
Product Safety
Market Thoughts This Labor Day Weekend
September 01, 2024
For this long weekend, I am offering you food for thought. In the overall macro theme, I am sticking to this for time being: Stagflation - The Fed can’t fix it with a huge reduction in rates, that will...
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Ozempic: Unexpected Anti-Aging Miracle Drug? Researchers Reveal Surprising Potential
August 31, 2024
Ozempic may offer unexpected anti-aging benefits, potentially improving health and reducing mortality rates, according to new research.
Via
Benzinga
3 No-Brainer Stocks to Buy in September
August 31, 2024
There's at least one key common denominator here: tremendous growth prospects.
Via
The Motley Fool
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
August 31, 2024
This competitive showdown just saw one of the players hit a couple of bumps.
Via
The Motley Fool
Looking At Novo Nordisk's Recent Unusual Options Activity
August 27, 2024
Via
Benzinga
What the Options Market Tells Us About Novo Nordisk
August 22, 2024
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,900 Today
August 20, 2024
Via
Benzinga
Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits
August 30, 2024
A Philadelphia judge's early ruling in the Ozempic and Wegovy litigation may shape the outcome of the lawsuits against Novo Nordisk and Eli Lilly, focusing on the diagnosis of gastroparesis and the...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
August 30, 2024
Novo Nordisk's semaglutide reduced the risk of cardiovascular events in heart failure patients by 31% in recent trials published by The Lancet. While not approved for heart failure outcomes in the US,...
Via
Benzinga
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
August 30, 2024
The addressable market for the treatments could potentially contract significantly.
Via
The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
August 29, 2024
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.
Via
Investor's Business Daily
Is Eli Lilly Stock a No-Brainer Buy After the Company's Brilliant Zepbound Move?
August 29, 2024
Some insurers don't cover Lilly's obesity drug. The company just gave patients a way around that problem.
Via
The Motley Fool
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
August 28, 2024
Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space.
Via
Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
August 27, 2024
The single-dose vials will also increase supply, the drug giant says.
Via
Investor's Business Daily
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
August 27, 2024
Shareholders don't have too much to fear -- yet.
Via
The Motley Fool
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
August 26, 2024
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited...
Via
Benzinga
Eli Lilly’s Path to the Next Trillion Market Capitalization
August 26, 2024
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.
Via
MarketBeat
Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices
August 26, 2024
Novo Nordisk CEO defends the high U.S. prices of Ozempic and Wegovy, arguing that the drugs reduce obesity-related costs. Senator Sanders and experts remain critical as a Senate hearing looms next...
Via
Benzinga
This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money
August 25, 2024
Its GLP-1 medicines are just one reason why it could threaten Novo Nordisk.
Via
The Motley Fool
2 No-Brainer Healthcare Stocks to Buy With $1,000
August 24, 2024
There are no certainties in equity markets, but these stocks look highly likely to deliver outsized returns.
Via
The Motley Fool
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
August 23, 2024
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,...
Via
Benzinga
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
August 23, 2024
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
Via
News Direct
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
August 23, 2024
Ozempic remains on top in the GLP-1 drug market -- but for how long?
Via
The Motley Fool
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
August 23, 2024
Vertex Pharmaceuticals has a lot going for it.
Via
The Motley Fool
Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages
August 21, 2024
Sesame introduces an affordable weight loss program with compounded versions of Wegovy amid supply shortages. The program provides a $249 monthly alternative to expensive obesity treatments.
Via
Benzinga
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
August 21, 2024
Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong bullish...
Via
Benzinga
Topics
Economy
Exposures
Supply Chain
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?
August 21, 2024
The Big Pharma stock is up by more than 50% in 2024, but investment-bank analysts think it has more room to run.
Via
The Motley Fool
Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
August 20, 2024
A recent study in JAMA Network Open raises concerns about a potential link between GLP-1 drugs Ozempic and Wegovy and an increased rate of suicidal thoughts after analyzing World Health Organization...
Via
Benzinga
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
August 19, 2024
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
62
63
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.